The market for infant formulas has become increasingly competitive over the past decade. Ingredients that manufacturers once included only in specialized formulas are now added to nearly all formulas. These ingredients come with marketing claims, such as “fosters cognitive development” and “supports digestive health.”
It is time to ask whether there are data to support these claims. On September 9, 2016, the US Food and Drug Administration (FDA) issued its first draft guidance on this topic, which outlines the quality of evidence that formula manufacturers should have to substantiate these claims, including randomized trials.1 The evidence currently available to the public does not meet these standards. For many claims there is no evidence available to the public, and when the results of randomized trials are made public, we learn that they are limited by small sample sizes, poor follow-up, and provide unpersuasive results.2 It is also important to understand how these claims may affect breastfeeding and public health budgets, and to consider regulatory approaches that might produce better publicly available evidence.
Hughes HK, Landa MM, Sharfstein JM. Marketing Claims for Infant Formula: The Need for Evidence. JAMA Pediatr. 2017;171(2):105–106. doi:https://doi.org/10.1001/jamapediatrics.2016.3837
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: